According to a report on Tuesday by The Fly, HC Wainwright lowered its price objective for BioXcel Therapeutics (NASDAQ: BTAI), bringing it down from $85.00 to $73.00. The report was based on a study that was released on Tuesday. The price objective provided by HC Wainwright represents a potential increase that is equivalent to a rise of 239.85 percent when measured against the stock’s most recent price.
Several additional equity analysts have recently provided their commentary on the stock while it was the topic of discussion. In a report published on Friday, November 11, Canaccord Genuity Group increased their price target on BioXcel Therapeutics stock from $75.00 to $76.00 and gave it a “buy” rating. Goldman Sachs Group upgraded BioXcel Therapeutics from a “sell” level to a “neutral” level in a research report disseminated on Thursday, December 1. In addition, the investment bank set a price objective of $16.00 for the stock. Both of these developments were included in the report. In a report distributed on Thursday, December 15, Mizuho raised their price target on BioXcel Therapeutics shares from $18.00 to $24.00. As part of a research report distributed on Friday, November 11, Guggenheim lowered their “buy” rating and their price objective on shares of BioXcel Therapeutics, moving them from $28.00 to $25.00. The move was made in conjunction with the publication of the report. Canaccord Genuity Group raised their price target on BioXcel Therapeutics from $75.00 to $76.00 and upgraded the company from a “hold” rating to a “buy” rating in a report released on Friday, November 11. In contrast to the seven financial analysts who gave the stock a buy rating, only one of the analysts polled recommended maintaining the stock’s current holdings. According to Bloomberg, the consensus price objective for the company has been set at $51.78, and the average rating for the company has been changed to “Moderate Buy.”
When the NASDAQ BTAI market opened for trading on Tuesday, the opening price was $21.48. A debt-to-equity ratio comes in at 0.72; a current ratio comes in at 10.34; a quick ratio comes in at 10.28; and a current ratio comes in at 10.34. The current P/E ratio for the company is -4.39, and it has a beta value of 1.16. The market capitalization of the company is $601.87 million. The company has seen a moving average of $14.69 over the past two hundred days, and the moving average over the last fifty days is $16.67. In the past fifty-two weeks, the price of BioXcel Therapeutics has ranged from its all-time low of $8.80 to its all-time high of $24.57. The current price of BioXcel Therapeutics is $8.80.
On November 10, BioXcel Therapeutics released its most recent quarterly earnings report. The company was trading on the NASDAQ under the ticker symbol BTAI. The company’s earnings per share for the quarter came in at $1.49%, which was $0.15% less than the estimated earnings per share of $1.34% that market experts had predicted. The company’s quarterly profits totaled $1.49%. The consensus expectation for revenue for the quarter was $3.05 million, a significant difference from the actual revenue for the quarter, which was only $0.14 million. According to industry analysts’ projections, BioXcel Therapeutics will finish the current financial year with a loss of -5.31 cents per share.
On November 10, Krishnan Nandabalan, Director of BioXcel Therapeutics, sold 27,450 shares of the company’s stock. The previous piece of news is connected to this one. There was $411,750.00 worth of transactions involving the company’s stock, with each share selling for an average price of $15.00. This page contains the filing containing the information about the transaction provided to the Securities and Exchange Commission (SEC). You can access the filing by clicking here. According to earlier reports concerning BioXcel Therapeutics, CEO Vimal Mehta sold 30,000 company stock on Friday, December 16. This transaction was reported in earlier news regarding the company. There was $583,200.00 worth of transactions involving the company’s stock, with each share changing hands at an average price of $19.44. After the completion of the transaction, the chief executive officer now directly owns 9,957 shares of the company. The total value of these shares is $193,564.08, so the total amount that the CEO has invested in the company is $193,564.08. You will be taken to a legal file submitted to the SEC if you click on the link we have provided, where you will find additional information regarding the sale. In addition, director Krishnan Nandabalan sold 27,450 shares of the company’s stock on Thursday, November 10. The stock was bought and sold for a total value of $411,750.00, corresponding to an average price of $15 per share. This resulted in income for the company. Disclosures that are related to the sale might be found in this section of the website. Currently, 37.00% of the company’s stock is owned by company insiders.
Recently, several institutional investors have modified the processes by which they invest their money in the company in various ways. Trust Financial Corporation was successful in adding 3.6% more shares of BioXcel Therapeutics to its portfolio over the second quarter. Trust Financial Corporation has increased the total number of shares it owns to 19,974, bringing the total value of those shares to USD 264,000 since the beginning of the most recent quarter. This increase was accomplished through the purchase of 694 additional shares. Price T. Rowe Associates Inc. (MD), during the second quarter, brought the total amount of BioXcel Therapeutics stock that it owned to a level that was 5.7% higher than before. Price T. Rowe Associates Inc. (MD) now owns 794 additional shares of the company’s stock, bringing the total number of shares owned by the company to 14,747, with a value of $195,000; these shares were purchased by Price T. Rowe Associates Inc. (MD). The value of Northern Trust Corporation’s holdings in BioXcel Therapeutics increased by 0.7 percent during the first three months of 2018. The current market value of Northern Trust Corporation’s holdings in the company, which consist of 194,604 shares, is $4,069,000. This resulted in a total of 1,297 additional shares being issued. The Bank of New York Mellon Corporation increased the amount of BioXcel Therapeutics stock owned by 2.9% over the first three months of 2018. Bank of New York Mellon Corp now has 58,386 shares of the company’s stock, valued at $1,220,000 after purchasing an additional 1,637 shares during the period in question. This brings the total number of shares owned by the company to 58,386. And finally, during the first three months of 2018, Wellington Management Group LLP saw a 7.1% increase in the total value of the holdings it had made in BioXcel Therapeutics. After making an additional purchase of 1,752 shares during the period in question, Wellington Management Group LLP now owns 26,394 shares of the company’s stock, which has a market value of $52,000. These shares were purchased during the period in question. Institutional investors own the common stock of the company to the extent of 42.35 percent.
BioXcel Therapeutics, Inc., a biopharmaceutical company that has reached the commercial stage of development, is attempting to develop game-changing medicines to treat cancers related to the nervous system and the immune system. These cancers include glioblastoma multiformeal company, which has reached the commercial stage of development and is attempting to develop game-changing medicines for treating cancers related to the nervous system and the immune system. These cancers include glioblastoma multiforme. The company’s drug re-innovation method integrates clinically validated product candidates, medications that have already been approved for use, massive amounts of data, and proprietary machine learning algorithms to discover new therapeutic indices. This is done to discover new therapeutic applications.
Read More: HC Wainwright has raised its price target on BioXcel Therapeutics (NASDAQ:BTAI) to